Fujifilm

FUJIFILM Biotechnologies is a leading contract development and manufacturing organization (CDMO) that specializes in biologics, vaccines, and advanced therapies. With major production facilities in the United States, the United Kingdom, and Denmark, the company is expanding its operations with a new large-scale cell culture production site in Holly Springs, North Carolina, set to be operational by 2025.

The company collaborates with biopharmaceutical and biotech firms to provide comprehensive end-to-end services, including proprietary cell line development, process and analytical development, clinical and commercial manufacturing, and fill and finish services. FUJIFILM Biotechnologies utilizes its proprietary KojoX™ operational ecosystem to ensure speed, flexibility, and reliability in production. Its facilities are FDA-approved for commercial production, supporting a wide range of biopharmaceutical products, including recombinant proteins, monoclonal antibodies, and vaccines. As part of FUJIFILM Holdings Corporation, the company is committed to creating social value and positive impact globally.